News Satralizumab Slashes Relapse Rate in Neuromyelitis Optica by Medscape • 2018/10/17 • 0 Comments First results from a phase 3 study suggest the biologic agent in development could improve outcomes among people with neuromyelitis optica spectrum disorder. Medscape Medical News Full Story →